Bone localising radiopharmaceutical and tubulin-interacting compound combination radiotherapy

The present invention relates to a method for the improved treatment of a cancerous disease in a patient and/or for the palliation of pain associated with cancer diseases, comprising the administration of a tubulin interacting compound in combination with a bone-localising radiopharmaceutical to said patient in an effective amount that will not cause any substantial ablation of the bone marrow of said patent. In particular, the cancerous disease is selected from the group of cancer diseases, comprising multiple myeloma, leukaemia, lymphoma, breast cancer, prostate cancer, gynecologic cancer, gastric cancer ovarian cancer, lung cancer and/or renal cell carcinoma. In a preferred embodiment, the bone-localising radiopharmaceutical is samarium Sm 153 lexidronam and the tubulin interacting compound is docetaxel.